Cargando…
Approaching patients with irritable bowel syndrome
Treatment of functional gastrointestinal disorders remains difficult with many very different approaches showing similar response rates, regardless of whether they target luminal contents (e.g., presumed bacterial overgrowth), signaling within the gut wall (e.g., serotonin agonists or antagonists) o...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medicine Reports Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950050/ https://www.ncbi.nlm.nih.gov/pubmed/20948834 http://dx.doi.org/10.3410/M2-50 |
_version_ | 1782187619740811264 |
---|---|
author | Bielefeldt, Klaus |
author_facet | Bielefeldt, Klaus |
author_sort | Bielefeldt, Klaus |
collection | PubMed |
description | Treatment of functional gastrointestinal disorders remains difficult with many very different approaches showing similar response rates, regardless of whether they target luminal contents (e.g., presumed bacterial overgrowth), signaling within the gut wall (e.g., serotonin agonists or antagonists) or processing in the brain (e.g., cognitive behavioral therapy). Discrepancies between recent clinical trials and a meta-analysis have forced us to re-examine the use of antidepressants. Other studies have looked beyond the traditional drug therapies and have suggested other options such as dietary interventions and communication strategies that address relevant disease mechanisms and enable us to understand patient concerns, with the ultimate goal being to individualize and thus improve treatment outcomes. |
format | Text |
id | pubmed-2950050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Medicine Reports Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-29500502010-10-14 Approaching patients with irritable bowel syndrome Bielefeldt, Klaus F1000 Med Rep Review Article Treatment of functional gastrointestinal disorders remains difficult with many very different approaches showing similar response rates, regardless of whether they target luminal contents (e.g., presumed bacterial overgrowth), signaling within the gut wall (e.g., serotonin agonists or antagonists) or processing in the brain (e.g., cognitive behavioral therapy). Discrepancies between recent clinical trials and a meta-analysis have forced us to re-examine the use of antidepressants. Other studies have looked beyond the traditional drug therapies and have suggested other options such as dietary interventions and communication strategies that address relevant disease mechanisms and enable us to understand patient concerns, with the ultimate goal being to individualize and thus improve treatment outcomes. Medicine Reports Ltd 2010-07-14 /pmc/articles/PMC2950050/ /pubmed/20948834 http://dx.doi.org/10.3410/M2-50 Text en © 2010 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes |
spellingShingle | Review Article Bielefeldt, Klaus Approaching patients with irritable bowel syndrome |
title | Approaching patients with irritable bowel syndrome |
title_full | Approaching patients with irritable bowel syndrome |
title_fullStr | Approaching patients with irritable bowel syndrome |
title_full_unstemmed | Approaching patients with irritable bowel syndrome |
title_short | Approaching patients with irritable bowel syndrome |
title_sort | approaching patients with irritable bowel syndrome |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950050/ https://www.ncbi.nlm.nih.gov/pubmed/20948834 http://dx.doi.org/10.3410/M2-50 |
work_keys_str_mv | AT bielefeldtklaus approachingpatientswithirritablebowelsyndrome |